Actively Recruiting
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Led by Center for International Blood and Marrow Transplant Research · Updated on 2023-08-30
650
Participants Needed
1
Research Sites
569 weeks
Total Duration
On this page
Sponsors
C
Center for International Blood and Marrow Transplant Research
Lead Sponsor
N
National Marrow Donor Program
Collaborating Sponsor
AI-Summary
What this Trial Is About
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
CONDITIONS
Official Title
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis
- Disease classified as intermediate-2 or high risk by DIPSS
- Age 55 years or older at the time of DIPSS assessment
- For alloHCT arm: donor must be either a 6/6 HLA-matched related donor (not identical twin) or an 8/8 HLA-matched unrelated donor
- Both peripheral blood stem cells and bone marrow grafts are allowed
- All conditioning regimen intensities and GVHD prophylaxis regimens are allowed
- Haploidentical donors allowed in the Haploidentical Donor Study
You will not qualify if you...
- Use of umbilical cord blood units or HLA-mismatched adult donors (< 6/6 for related or < 8/8 for unrelated donors) for alloHCT
- Presence of overlap syndromes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for International Blood and Marrow Transplant Research
Minneapolis, Minnesota, United States, 55401
Actively Recruiting
Research Team
P
Patricia Steinert, PhD
CONTACT
S
Stephanie Farnia
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here